JPRN-UMIN000010346RecruitingPhase 2
A phase 2 study of cyclophosphamide, lenalidomide and dexamethasone (CRD) for patients with relapsed/refractory multiple myeolma - A phase 2 study of CRD for patients with relapsed/refractory multiple myeolma
The Jikei University School of Medicine0 sites35 target enrollmentStarted: March 28, 2013Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Recruiting
- Enrollment
- 35
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1. Non-secretory type multiple myeloma 2. Plasma cell leukemia 3. Ca >= 14mg/dl 4. Allergy to cyclophosphamide, lenalidomide, and dexamethasone 5. Plan for PBSCH 6. Active infection 7. Hemorrhagic diathesis, and coagulation disorder 8. Uncontrollable diabetes mellitus, hypertension, angina pectoris or congestive heart failure 9. HBV, HCV, and HIV infection 10. Impossibility to receive anti-coagulation agents 11. History of operation in 4 weeks 12. History of radiation therapy in 2 weeks 13. History of anti-cancer therapy, biological therapy, and immunological therapy 14. History of allogeneic transplant 15. Pregnancy 16. Doctor judged inadequate to enroll the study
Investigators
Similar Trials
Active, not recruiting
Not Applicable
An open-label, phase II study of cyclophosphamide, lenalidomide and dexamethasone (CLD) for previously treated patients with AL amyloidosis - NDEUCTR2007-006037-13-ITOSPEDALE POLICLINICO S. MATTEO
Active, not recruiting
Phase 1
Graft-versus-host response after reduced-intensity conditioning allogeneic peripheral blood stem cell transplantatioWomen and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicatedMedDRA version: 19.0Level: PTClassification code 10053239Term: Prophylaxis against graft versus host diseaseSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2016-002129-12-FRASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)88
Not yet recruiting
Not Applicable
Phase II study of lenalidomide-R-CHOP for patients with diffuse large B cell lymphoma who are at high risk of central nervous system relapseKCT0005165Asan Medical Center100
Completed
Phase 1
Safety and efficacy of lenalidomide cyclophosphamide and dexamethasone (RCd) therapy in Japanese elderly patients with multiple myeloma, a phase I/II studyMultiple MyelomaJPRN-UMIN000009391KT-MM30
Active, not recruiting
Not Applicable
Cyclophosphamide and Dexamethasone in combination with Ixazomib (ICD), in relpased or refractory multiple myeloma patients.Relasped and Refractory Mulitple MyelomaMedDRA version: 18.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2014-004511-36-GBniversity Of Leeds250